46,982 Shares in Prime Medicine, Inc. (NYSE:PRME) Acquired by SG Americas Securities LLC

SG Americas Securities LLC acquired a new stake in Prime Medicine, Inc. (NYSE:PRME) during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 46,982 shares of the company’s stock, valued at approximately $182,000.

A number of other large investors also recently modified their holdings of the company. ORG Partners LLC purchased a new position in Prime Medicine in the second quarter valued at $29,000. National Bank of Canada FI acquired a new position in shares of Prime Medicine during the 2nd quarter worth about $34,000. Nisa Investment Advisors LLC boosted its position in shares of Prime Medicine by 22,652.9% during the 2nd quarter. Nisa Investment Advisors LLC now owns 7,736 shares of the company’s stock worth $40,000 after acquiring an additional 7,702 shares in the last quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd purchased a new position in shares of Prime Medicine in the 2nd quarter valued at about $97,000. Finally, ProShare Advisors LLC raised its position in shares of Prime Medicine by 19.8% during the 1st quarter. ProShare Advisors LLC now owns 15,276 shares of the company’s stock worth $107,000 after acquiring an additional 2,520 shares in the last quarter. 70.37% of the stock is owned by hedge funds and other institutional investors.

Prime Medicine Trading Down 10.5 %

Shares of PRME opened at $3.99 on Thursday. The company’s 50 day simple moving average is $3.93 and its 200-day simple moving average is $5.14. The firm has a market cap of $478.92 million, a PE ratio of -1.84 and a beta of 2.18. Prime Medicine, Inc. has a 12-month low of $3.28 and a 12-month high of $9.86.

Prime Medicine (NYSE:PRME) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.06). As a group, equities research analysts forecast that Prime Medicine, Inc. will post -1.75 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. Wedbush reaffirmed an “outperform” rating and issued a $12.00 price target on shares of Prime Medicine in a report on Thursday, August 8th. HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Prime Medicine in a report on Wednesday, October 2nd. Finally, StockNews.com raised shares of Prime Medicine to a “sell” rating in a research report on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Prime Medicine has an average rating of “Moderate Buy” and an average target price of $13.50.

About Prime Medicine

Prime Medicine, Inc, a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence.